Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02997761 · ClinicalTrials.gov registry record · Phase 2
Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia
A Phase 2 study of Philadelphia Chromosome Positive and Adult B Acute Lymphoblastic Leukemia, sponsored by Brian Jonas.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT02997761 is a Phase 2 study of Philadelphia Chromosome Positive and Adult B Acute Lymphoblastic Leukemia that is actively recruiting participants, run by Brian Jonas. The registered enrollment target is 20 participants, below the 908-participant average among 11 other Philadelphia Chromosome Positive trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02997761, a Phase 2 study of Philadelphia Chromosome Positive and Adult B Acute Lymphoblastic Leukemia, is actively recruiting participants, sponsored by Brian Jonas.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well ibrutinib and blinatumomab work in treating patients with B acute lymphoblastic leukemia that has come back or is not responding to treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as blinatumomab, may interfere with the ability of cancer cells to grow and spread. Giving ibrutinib and blinatumomab may work better in treating patients with relapsed or refractory B acute lymphoblastic leukemia.
Conditions Studied
Interventions
- BIOLOGICAL Blinatumomab
- DRUG Ibrutinib
Study Locations (1)
California
- University of California Davis Comprehensive Cancer Center - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-06-27 |
| Est. Completion | 2025-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02997761
The ClinicalTrials.gov registry entry for NCT02997761 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 908-participant average among 11 other Philadelphia Chromosome Positive trials with a reported enrollment target (98% lower). The listed sponsor is Brian Jonas, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Philadelphia Chromosome Positive appearing as the primary indexed condition, and to 2 interventions - of which Blinatumomab is the first listed.
NCT02997761 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02997761 about?
NCT02997761 is a clinical study titled "Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia". This phase II trial studies how well ibrutinib and blinatumomab work in treating patients with B acute lymphoblastic leukemia that has come back or is not responding to treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibod...
What is the current status of trial NCT02997761?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2017-06-27. Estimated completion is 2025-09.
What conditions does trial NCT02997761 study?
This clinical trial studies the following conditions: Philadelphia Chromosome Positive, Adult B Acute Lymphoblastic Leukemia.
What interventions are being tested in trial NCT02997761?
The interventions under investigation include: Blinatumomab (BIOLOGICAL), Ibrutinib (DRUG).
Who is sponsoring clinical trial NCT02997761?
This trial is sponsored by Brian Jonas, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02997761 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Philadelphia Chromosome Positive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
RECRUITING · Phase 2
-
ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase
RECRUITING · Phase 2
-
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
RECRUITING · Phase 2
-
Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia
ACTIVE NOT RECRUITING · Phase 2
-
Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
ACTIVE NOT RECRUITING · Phase 2
-
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
COMPLETED · Phase 2
Explore more on PlainTrial
Philadelphia Chromosome Positive
All registered trials for this condition
Adult B Acute Lymphoblastic Leukemia
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.